Adaptive Biotechnologies Corporation · NASDAQ:ADPT
Adaptive Biotechnologies — Q4 2021 Earnings Presentation
15 slides from Adaptive Biotechnologies's earnings presentation, 2022
Slide 1: Fourth Quarter and FY 2021 Earnings Conference Call
Fourth Quarter and FY 2021 Earnings Conference Call
Slide 2: Safe Harbor
Safe Harbor This presentation has been prepared by Adaptive Biotechnologies Corporation (“we,” “us,” “our,” “Adaptive” or the “Company”) and is made for informational purposes only. The information set forth herein does not purport to be complete or to contain all relevant information. Statements co
Slide 3: Business areas of focus going forward
Business areas of focus going forward MRD Immune Medicine Driven by clonoSEQ/MRD assay applications Driven by immune receptor data opportunities TAM ~$6B1 TAM ~$48B2 Drug Discovery Clinical MRD Clinical Pharma Cell Therapy Testing Pharma Testing Services Vaccines 1. Global TAM: $4.5B clonoSEQ clinic
Slide 4: Key Achievements through 2021
Key Achievements through 2021 MRD Business ◼ Key data read outs demonstrating clinical utility ◼ Expanded commercial team, added product line enhancements for CLL patients ◼ Signed 2 significant pan-portfolio MRD partnerships across all heme indications ◼ Recognized $10M in milestones from pharma pa
Slide 5: Our MRD Heme business: synergistic value of pharma and clinical diagnostic
Our MRD Heme business: synergistic value of pharma and clinical diagnostic Tests Delivered ‘21 > 60 Companies • Q4: 6,356 (+7% vs Q3) • FY: 22,516 (+48% Y/Y) 155 Active trials Ordering HCPs MRD > $330M Milestones • 1,735 (+57% Y/Y) Clinical Testing Pharma Trials Embedded as clinical Ordering Account
Slide 6: Immune Medicine Strategy
Unique ability to map & identify disease specific TCR sequences Pharma Diagnostics Services Immune Medicine Strategy Disease Specific Create multiple value TCR-Antigen opportunities stemming Data from the same core disease data Drug Discovery 6
Slide 7: T-Detect, advancing towards "one test, many diseases"
T-Detect, advancing towards “one test, many diseases” COVID AUTOIMMUNE LYME Only FDA authorized test, Clinical signals in five diseases ImmuneSense Study available to consumers Crohn’s, UC, celiac, MS, RA Completed ◼ Focus on studying correlate of ◼ Maintain high specificity (rule-in) ◼ Enable CLIA
Slide 8: Genentech selects TCR candidate against a shared cancer neoantigen
Genentech selects TCR candidate against a shared cancer neoantigen Cell Therapy – Progress on Shared and Private Programs Shared ◼ TCR candidate selected to progress as a potential therapeutic product candidate TCRs targeting shared cancer ◼ Efficacy and safety data reviewed by both Adaptive and Gen
Slide 9: Q4 and FY 2021 Financial Highlights
Q4 and FY 2021 Financial Highlights Revenues ($M) 1 Operating Expenses ($M) 1 $363.3 Sequencing Development +45% $154.3 +57% $99.5 $251.2 $37.9 +26% $98.4 +34% $30.2 78.9 +90% $74.4 23.1 +81% 12.7 41.4 +32% -15% 75.4 17.5 14.9 56.9 Q4 2020 Q4 2021 FY 2020 FY 2021 Q4 2020 Q4 2021 FY 2020 FY 2021 Sequ
Slide 10: FY 2022 Guidance
FY 2022 Guidance ◼ Revenue: 2022 full year revenue range $185M - $195M ❑ Sequencing revenue represents ~60% of total revenue at mid-point of range ❑ Include low to mid double digit in potential milestones (risk-adjusted) ❑ Q1 expected to be the lowest quarter of the year with no milestone anticipate
Slide 11: Key Catalysts 2022 -- Multiple levers to drive value
Key Catalysts 2022 -- Multiple levers to drive value ◼ T-Detect COVID: Enhance product profile (correlate of protection) ◼ T-Detect AI: Increase sensitivity/specificity in MS, IBD, RA for market readiness Immune ◼ Genentech collaboration: ✓ Selected TCR candidate to progress as a potential therapeut
Slide 12: Thank You.
Thank You.
Slide 13: Appendix: clonoSEQ Pipeline
Appendix: clonoSEQ Pipeline 13
Slide 14: Appendix: Drug Discovery Pipeline
Appendix: Drug Discovery Pipeline 14
Slide 15: Appendix: T-Detect Pipeline
Appendix: T-Detect Pipeline 15
Adaptive Biotechnologies — Q4 2021 Earnings Presentation on 6ix